deltatrials
Completed PHASE1/PHASE2 NCT00187109

Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy

A Phase I/II Trial of Recombinant Human Thrombopoietin in Children With Malignant Solid Tumors and Lymphoma Receiving Ifosfamide, Carboplatin and Etoposide

Sponsor: St. Jude Children's Research Hospital

Conditions Germ Cell Tumors Hepatic Cancer Neuroblastoma Osteosarcoma Rhabdomyosarcoma
Interventions Recombinant Human Thrombopoietin
Updated 5 times since 2017 Last updated: Apr 8, 2008 Started: Jun 30, 2000 Primary completion: Feb 28, 2007 Completion: Feb 28, 2007

Listed as NCT00187109, this PHASE1/PHASE2 trial focuses on Germ Cell Tumors and Hepatic Cancer and remains completed. Sponsored by St. Jude Children's Research Hospital, it has been updated 5 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jun 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • St. Jude Children's Research Hospital
Data source: St. Jude Children's Research Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Memphis, United States